Molina Healthcare Inc

Molina Healthcare delivered a sharply mixed first quarter of 2026, posting adjusted diluted EPS of $2.35 and topping the $1.94 consensus estimate by 21.40%, even as revenue of $10.80 billion came in just 0.83% below expectations and fell 3.1% from a year ago. The headline profit beat, however, obscures a quarter defined by significant strain: GAAP net income collapsed to $14.00 million from $298.00 million a year earlier, weighed down by a $93.00 million impairment charge tied to the company's decision to exit its Medicare Advantage Prescription Drug product for 2027 and redirect focus toward dual-eligible members, a shift that investors tracking <a href="https://247wallst.com/investing/2026/04/22/will-the-new-medicare-rates-boost-finally-lift-molina-healthcare/">the Medicare rate environment</a> have been watching closely. Total membership declined to approximately 5.0 million from 5.75 million a year ago, and the consolidated medical care ratio deteriorated to 91.1% from 89.2%, reflecting broad cost pressure across Medicaid and Medicare segments. Molina reaffirmed full-year 2026 guidance for premium revenue of roughly $42.00 billion and adjusted EPS of at least $5.00, with a formal guidance update expected following second-quarter results.